The distinctive nature of HER2-positive breast cancers.
@article{Burstein2005TheDN, title={The distinctive nature of HER2-positive breast cancers.}, author={H. Burstein}, journal={The New England journal of medicine}, year={2005}, volume={353 16}, pages={ 1652-4 } }
The history of HER2 and trastuzumab treatment is a triumphal narrative of translational research. Dr. Harold Burstein writes that like all good stories, this one has a profound lesson: not all breast cancers are the same.
Topics from this paper
Paper Mentions
Interventional Clinical Trial
To evaluate the safety, dosimetry and efficacy of 99mTc/188Re labeled anti-HER2 single domain
antibody (sdAb) (Product Code Name: 99mTc-NM02 and 188Re-NM02) SPECT/CT imaging of HER2… Expand
Conditions | Breast Cancer |
---|---|
Intervention | Drug |
Interventional Clinical Trial
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel,
use different ways to stop tumor cells from dividing so they stop growing or die… Expand
Conditions | Breast Cancer |
---|---|
Intervention | Biological, Drug |
Interventional Clinical Trial
Based on these results it can be envisioned that the majority of endocrine-responsive
post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy
(front… Expand
Conditions | Metastatic Breast Cancer |
---|---|
Intervention | Drug |
373 Citations
From tumor size and HER2 status to systems oncology for very early breast cancer treatment
- Medicine
- Expert review of anticancer therapy
- 2010
- 67
HER2 status in breast cancer--an example of pharmacogenetic testing.
- Medicine
- Journal of the Royal Society of Medicine
- 2007
- 25
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
- Medicine
- Journal of the National Comprehensive Cancer Network : JNCCN
- 2018
- 284
- PDF
Retraction Note to: SOX2 oncogenes amplified and operate to activate AKT signalling in gastric cancer and predict immunotherapy responsiveness
- Medicine, Biology
- Journal of Cancer Research and Clinical Oncology
- 2019
- PDF
Triple negative invasive lobular carcinoma of the breast presents as small bowel obstruction
- Medicine
- International journal of surgery case reports
- 2017
References
SHOWING 1-6 OF 6 REFERENCES
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
- Medicine
- The New England journal of medicine
- 2005
- 4,487
- PDF
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
- Biology, Medicine
- Nature
- 2003
- 1,324
- PDF
Untangling the ErbB signalling network
- Biology, Medicine
- Nature Reviews Molecular Cell Biology
- 2001
- 5,941
- PDF
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
- Medicine
- The New England journal of medicine
- 2005
- 4,905
- PDF
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
- Biology, Medicine
- Science
- 1987
- 10,825
- PDF